Current advances in antitubercular drug discovery: potent prototypes and new targets
Contribuinte(s) |
Universidade Estadual Paulista (UNESP) |
---|---|
Data(s) |
07/12/2015
07/12/2015
2015
|
Resumo |
Tuberculosis (TB) is an infectious disease caused by bacterium of the Mycobacterium genus, mainly by Mycobacterium tuberculosis (MTB). The World Health Organization aims to substantially reduce the number of cases in the coming years; however, the increased number of multidrug-resistant (MDR) and extremely drug-resistant (XDR) forms of the bacterium and the lack of treatment for latent tuberculosis are challenges to be overcome. In this review, we have identified the most potent compounds described in the literature during recent years with MIC values < 7 µM, low toxicity and a high selective index. In addition, emerging targets in MTB are presented to provide new perspectives for the discovery of new antitubercular drugs. This review aims to summarize the current advances in and promote insights into antitubercular drug discovery. |
Formato |
3133-3161 |
Identificador |
http://dx.doi.org/10.2174/0929867322666150818103836#sthash.EOREFJmy.dpuf Current Medicinal Chemistry, v. 22, n. 27, p. 3133-3161, 2015. 1875-533X http://hdl.handle.net/11449/131461 10.2174/0929867322666150818103836#sthash.EOREFJmy.dpuf 26282941 |
Idioma(s) |
eng |
Publicador |
Bentham Science Publishers |
Relação |
Current Medicinal Chemistry |
Direitos |
closedAccess |
Palavras-Chave | #Antitubercular drugs #Drug discovery #Mycobacterium tuberculosis #Resistant tuberculosis #Tuberculosis #Tuberculosis targets |
Tipo |
info:eu-repo/semantics/article |